New drug HRS-1635 targets tough blood cancers in early trial
NCT ID NCT07583212
First seen May 14, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This early-phase study tests a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. The main goal is to check the drug's safety and find the best dose. Researchers will also see if it helps shrink tumors, but this is a first step to see if the drug is safe enough for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital
Chengdu, Sichuan, 610041, China
Contact
Conditions
Explore the condition pages connected to this study.